BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1288 related articles for article (PubMed ID: 19416245)

  • 1. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial.
    Leung DY; Hanifin JM; Pariser DM; Barber KA; Langley RG; Schlievert PM; Abrams B; Hultsch T
    Br J Dermatol; 2009 Aug; 161(2):435-43. PubMed ID: 19416245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial.
    Gong JQ; Lin L; Lin T; Hao F; Zeng FQ; Bi ZG; Yi D; Zhao B
    Br J Dermatol; 2006 Oct; 155(4):680-7. PubMed ID: 16965415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial.
    Hoeger PH; Lee KH; Jautova J; Wohlrab J; Guettner A; Mizutani G; Hultsch T
    Br J Dermatol; 2009 Feb; 160(2):415-22. PubMed ID: 19067708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
    Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
    Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
    Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
    J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pimecrolimus cream 1% is effective in asteatotic eczema: results of a randomized, double-blind, vehicle-controlled study in 40 patients.
    Schulz P; Bunselmeyer B; Bräutigam M; Luger TA
    J Eur Acad Dermatol Venereol; 2007 Jan; 21(1):90-4. PubMed ID: 17207174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis.
    Siegfried E; Korman N; Molina C; Kianifard F; Abrams K
    J Dermatolog Treat; 2006; 17(3):143-50. PubMed ID: 16854753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease.
    Zuberbier T; Bräutigam M
    J Eur Acad Dermatol Venereol; 2008 Jun; 22(6):718-21. PubMed ID: 18312323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life.
    McKenna SP; Whalley D; de Prost Y; Staab D; Huels J; Paul CF; van Assche D
    J Eur Acad Dermatol Venereol; 2006 Mar; 20(3):248-54. PubMed ID: 16503881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis.
    Langley RG; Eichenfield LF; Lucky AW; Boguniewicz M; Barbier N; Cherill R
    Pediatr Dermatol; 2008; 25(3):301-7. PubMed ID: 18577032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial.
    Gollnick H; Kaufmann R; Stough D; Heikkila H; Andriano K; Grinienko A; Jimenez P;
    Br J Dermatol; 2008 May; 158(5):1083-93. PubMed ID: 18341665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
    Hebert AA
    Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis.
    Sigurgeirsson B; Ho V; Ferrándiz C; Andriano K; Grinienko A; Jimenez P;
    J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1290-301. PubMed ID: 18624866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial.
    Spergel JM; Boguniewicz M; Paller AS; Hebert AA; Gallagher PR; McCormick C; Parneix-Spake A; Hultsch T
    Br J Dermatol; 2007 Aug; 157(2):378-81. PubMed ID: 17573885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis.
    Ruer-Mulard M; Aberer W; Gunstone A; Kekki OM; López Estebaranz JL; Vertruyen A; Guettner A; Hultsch T
    Pediatr Dermatol; 2009; 26(5):551-8. PubMed ID: 19840309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.
    Gribetz C; Ling M; Lebwohl M; Pariser D; Draelos Z; Gottlieb AB; Zaias N; Chen DM; Parneix-Spake A; Hultsch T; Menter A
    J Am Acad Dermatol; 2004 Nov; 51(5):731-8. PubMed ID: 15523351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial.
    Kaufmann R; Bieber T; Helgesen AL; Andersen BL; Luger T; Poulin Y; Al-Hafidh J; Paul C;
    Allergy; 2006 Mar; 61(3):375-81. PubMed ID: 16436149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study.
    Schachner LA; Lamerson C; Sheehan MP; Boguniewicz M; Mosser J; Raimer S; Shull T; Jaracz E;
    Pediatrics; 2005 Sep; 116(3):e334-42. PubMed ID: 16140675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial.
    Wolff K; Fleming C; Hanifin J; Papp K; Reitamo S; Rustin M; Shear N; Silny W; Korman N; Marks I; Cherill R; Emady-Azar S; Paul C;
    Br J Dermatol; 2005 Jun; 152(6):1296-303. PubMed ID: 15948996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis.
    Warshaw EM; Wohlhuter RJ; Liu A; Zeller SA; Wenner RA; Bowers S; Schultz JC; Katz HI; McCormick CL; Parneix-Spake A
    J Am Acad Dermatol; 2007 Aug; 57(2):257-64. PubMed ID: 17188780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.